Legal & General Group’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.5K Buy
4,714
+514
+12% +$4.91K ﹤0.01% 2805
2026
Q1
$38.3K Sell
4,200
-673
-14% -$5.64K ﹤0.01% 2744
2025
Q4
$36.3K Sell
4,873
-266
-5% -$1.91K ﹤0.01% 2815
2025
Q3
$34.4K Sell
5,139
-66,270
-93% -$460K ﹤0.01% 2829
2025
Q2
$473K Buy
71,409
+35,873
+101% +$254K ﹤0.01% 2459
2025
Q1
$325K Hold
35,536
﹤0.01% 2526
2024
Q4
$373K Buy
35,536
+31,975
+898% +$378K ﹤0.01% 2561
2024
Q3
$42.6K Hold
3,561
﹤0.01% 2812
2024
Q2
$20.5K Buy
+3,561
New +$19.5K ﹤0.01% 3006
2023
Q2
Sell
-2,674
Closed -$2.88K 3428
2023
Q1
$2.88K Sell
2,674
-7,447
-74% -$14.2K ﹤0.01% 3337
2022
Q4
$26.4K Hold
10,121
﹤0.01% 3092
2022
Q3
$71K Hold
10,121
﹤0.01% 2902
2022
Q2
$69K Buy
10,121
+7,364
+267% +$75.1K ﹤0.01% 2938
2022
Q1
$39K Hold
2,757
﹤0.01% 3046
2021
Q4
$40K Buy
2,757
+1,127
+69% +$16K ﹤0.01% 3078
2021
Q3
$23K Buy
1,630
+819
+101% +$12.6K ﹤0.01% 3222
2021
Q2
$14K Buy
811
+111
+16% +$1.79K ﹤0.01% 3390
2021
Q1
$11K Buy
+700
New +$9.97K ﹤0.01% 3344

Other funds holding BVS

Legal & General Group's BVS Position: Q2 2026 in Review

Legal & General Group increased its Bioventus (BVS) stake by 12% in Q2 2026, buying an estimated $4.91K and bringing the position to 4,714 shares worth $44.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Legal & General Group first reported a position in BVS in Q1 2021 and has held it in 18 quarters since. The position peaked at $473K in Q2 2025. 156 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Legal & General Group held 4,714 shares of Bioventus worth $44.5K as of Q2 2026.
  • Legal & General Group bought 514 Bioventus shares in Q2 2026, an estimated $4.91K.
  • Bioventus made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2805 holding.
  • Legal & General Group first reported a position in Bioventus in Q1 2021 and has held it in 18 quarters since.
  • Legal & General Group's Bioventus position peaked at $473K in Q2 2025.
  • 156 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.